Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study

Rheumatology (United Kingdom)

Volumn 53, Issue 10, 2014, Pages 1830-1834

  Pope, Janet ^a   Walker, Kyle M ^b   Leon, Faye de ^c   Vanderhoek, Louise ^a   Seney, Shannon ^d   Summers, Kelly L ^a,d  

^a WESTERN UNIVERSITY   (Canada)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c MCMASTER UNIVERSITY   (Canada)

^d LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^e ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

Cytokines; Diffuse SSs; Early phase trial; Imatinib; Proof of concept; SSc

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; IMATINIB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; RANTES; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SCORING SYSTEM; SKIN BIOPSY; SYSTEMIC SCLEROSIS; TISSUE HOMOGENATE; TISSUE LEVEL;

EID: 84924847846     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu216     Document Type: Article

References (19)

1. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202–5.
2. Kowal-Bielecka O, Landewé R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620–8.
3. Furst DE. Rational therapy in the treatment of systemic sclerosis. Curr Opin Rheumatol 2000;12:540–4.
4. Clements PJ, Seibold JR, Furst DE et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum 2004;33:249–63.
5. Pope JE, Bellamy N, Seibold JR et al. A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351–8.
6. Leask A. Possible strategies for anti-fibrotic drug intervention in scleroderma. J Cell Commun Signal 2011;5: 125–9.
7. Akhmetshina A, Venalis P, Dees C et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60:219–24.
8. Pope JE, McBain D, Petrlich L et al. Imatinib in active diffuse systemic sclerosis: a single site trial. Arthritis Rheum 2011;63:3547–51.
9. Yamane K, Ihn H, Kubo M et al. Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma. J Am Acad Dermatol 2000;42:64–9.
10. Kurasawa K, Hirose K, Sano H et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000;43:2455–63.
11. Lafyatis R, York M. Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol 2009;21:617–22.
12. Asarch A, Barak O, Loo DS, Gottlieb AB. Th17 cells: a new therapeutic target in inflammatory dermatoses. J Dermatolog Treat 2008;19:318–26.
13. Komura K, Fujimoto M, Yanaba K et al. Blockade of CD40/ CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Ann Rheum Dis 2008;67:867–72.
14. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 2005;24:111–6.
15. Allanore Y, Borderie D, Meune C et al. Increased plasma soluble CD-40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers. Ann Rheum Dis 2005;64:481–3.
16. Yamakage A, Kikuchi K, Smith EA, LeRoy EC, Trojanowska M. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992; 175:1227–34.
17. Sgonc R, Wick G. Pro- and anti-fibrotic effects of TGF-b in scleroderma. Rheumatology 2008;47(Suppl 5): 5–7.
18. Badea I, Taylor M, Rosenberg A, Foldvari M. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology 2009;48:213–21.
19. Liakoll V, Cipriani P, Alvaro S et al. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 2011;10:590–4.